Prescient Therapeutics LimitedASX: PTX

Appendix 4E and 2025 Annual Report

· Issued by Prescient Therapeutics Limited

Filed with ASX · · 53 pages · English

Summary by 6ix AI

The report indicates a loss for the consolidated entity after tax, alongside a significant increase in research and development tax incentive rebates for eligible expenses. No dividends were declared during the current or previous financial year, reflecting the company's focus on development activities.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Prescient Therapeutics Limited on 6ix

Story so far

Earlier from Prescient Therapeutics

Later from Prescient Therapeutics

All Prescient Therapeutics news releases